KROMATID Blog
Experimental Design: The Foundation of Successful Cell & Gene Therapy Development Genomic Integrity Cell and Gene Therapy iPSC Therapy Starting Material Analysis In cell and gene therapy, every decision made during development has the potential to impact patient safety, product quality, regulatory success, and ultimately, commercial viability. While tremendous attention is often placed on vector design, editing efficiency, and manufacturing processes, one critical component is sometimes overlooked: thoughtful experimental design.
Genomic Integrity: The Fourth Pillar of Quality in Cell and Gene Therapy Cell and Gene Therapy For decades, the biopharmaceutical industry has relied on three foundational quality attributes to evaluate therapeutic products:
The Biggest Risk in In Vivo Therapeutic Engineering Is What We Cannot See in vivo In vivo therapeutic engineering is often framed as the next logical evolution of ex vivo cell and gene therapy. By eliminating complex manufacturing steps and enabling direct delivery of therapeutic payloads into the body, these approaches promise broader access, faster treatment timelines, and potentially lower cost.
The Next Evolution of Cytogenetics: From Observation to Action FDA Guidance Cell and Gene Therapy For decades, cytogenetics has played a critical role in therapy development. It has helped us see when genomes are altered, unstable, or outright broken. But as cell and gene therapies become more sophisticated - and the margin for error shrinks - seeing is no longer enough.
All HSCs Are Not Created Equal: The Importance of Testing Your Starting Material Genomic Integrity Starting Material Analysis HSC's Hematopoietic stem cells (HSCs) sit at the foundation of many cell and gene therapy programs. Whether used in autologous or allogeneic settings, ex vivo gene editing or viral transduction, HSCs are often treated as a standardized input—assumed to be equivalent as long as basic identity, viability, and purity criteria are met.
2025: A Pivotal Year for Genomic Insight - and What Comes Next in 2026 Allogeneic Cell Therapy Cell and Gene Therapy Despite numerous challenges, the cell and gene therapy (CGT) sector has never moved faster. In 2025, we saw breakthroughs in precision editing, rapid scale-up of manufacturing platforms, and renewed investor attention on therapies with clear clinical differentiation. But alongside the scientific momentum, one theme stood out more than any other: genomic stability is now a defining hallmark for safety, reproducibility, and regulatory confidence.
Ensuring Genomic Integrity in Allogeneic Cell Therapy Development Genomic Integrity CAR-NK Therapy Allogeneic Cell Therapy Cell and Gene Therapy iPSC Therapy CAR-T Ensuring Genomic Integrity in Allogeneic Cell Therapy Development
Navigating the Hidden Risks of CRISPR with the KROMASURE™ Platform CRISPR A recent Perspective in Nature Communications, “The hidden risks of CRISPR/Cas: structural variations and genome integrity” (August 5, 2025), emphasizes a growing concern in gene editing: while CRISPR technology enables powerful genomic interventions, unintended outcomes—such as kilobase- to megabase-scale deletions, chromosomal translocations, and broader structural variations (SVs)—pose serious safety and regulatory challenges Nature. These risks are especially pronounced as therapeutic genome editing advances toward clinical applications.
🧬 A New Era in Drug Development: How KROMATID Advances Human Research in a Post-Animal Testing World In a landmark decision, the FDA has removed its decades-old requirement for animal testing before human clinical trials. This shift signals a bold new era—one that prioritizes more predictive, human-relevant data over legacy animal models that often fail to translate into successful therapies.
🔬 Where KROMATID Supports CMC for Cell & Gene Therapies Bringing Genomic Clarity to Chemistry, Manufacturing, and Controls
Why Use OGM + Karyotyping Together in Genome-Edited Cell Analysis karyotyping optical genome mapping
KROMASURE™ for Starting Material Analysis: Setting the Foundation for Safer, Smarter Therapies In cell and gene therapy development, everything begins with the starting material — the raw cellular input that ultimately becomes the therapeutic product. Whether you're working with patient-derived cells, donor cells, or engineered lines, the genomic integrity of your starting material directly impacts product quality, safety, and regulatory success.
KROMASURE PinPoint™: High-Throughput Transgene Integration Analysis at Single-Cell Resolution The Gold Standard for Non-Metaphase Genomic Insight In the evolving landscape of cell and gene therapy, understanding where and how transgenes integrate into the genome is not just a scientific curiosity — it’s a regulatory and therapeutic imperative. While sequencing remains a cornerstone of genomic analysis, it often lacks the cellular granularity needed to fully characterize insertion events. That’s where KROMASURE PinPoint™ steps in.
Navigating the 2024 FDA Guidance Updates for Cell and Gene Therapy​ FDA Guidance The field of cell and gene therapy (CGT) has witnessed remarkable advancements in recent years. To keep pace with these innovations and ensure patient safety, the U.S. Food and Drug Administration (FDA) released several guidance documents in 2024. These documents provide clarity on regulatory expectations, aiming to streamline development processes and uphold high safety standards. Key FDA Guidance Documents from 2024 Human Gene Therapy Products Incorporating Human Genome Editing (January 2024) This guidance offers comprehensive recommendations for sponsors developing gene therapy products that involve genome editing. It emphasizes the importance of evaluating off-target effects, ensuring genomic integrity, and conducting thorough preclinical studies to assess potential risks associated with genome editing technologies. ASGCT Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products (January 2024) Focusing on CAR T-cell therapies, this guidance outlines considerations for product development, including manufacturing processes, preclinical testing, and clinical trial design. It addresses the unique challenges posed by these personalized therapies and provides a framework for their safe and effective development. ASGCT Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products (April 2024) This draft guidance assists sponsors in designing appropriate safety testing strategies for allogeneic cell-based products. It highlights the need for rigorous testing to detect potential contaminants and ensure the quality and safety of expanded cell populations used in therapeutic applications. www.aabb.org Considerations for the Use of Human- and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products (April 2024) Addressing the use of materials derived from human and animal sources, this draft guidance provides recommendations to mitigate risks associated with transmissible agents. It underscores the importance of sourcing, testing, and documenting these materials to ensure product safety. www.aabb.org Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products (November 2024) This draft guidance compiles responses to common questions encountered during CGT product development. It serves as a consolidated resource, offering insights into regulatory considerations across various aspects of product development, including manufacturing, preclinical studies, and clinical trials. U.S. Food and Drug Administration Implications for Developers The 2024 FDA guidance documents reflect the agency's commitment to facilitating the development of safe and effective CGT products. By providing clear regulatory expectations, these guidances help developers navigate complex development pathways, reduce uncertainties, and expedite the delivery of innovative therapies to patients. Conclusion Staying informed about regulatory developments is crucial for stakeholders in the CGT field. The FDA's 2024 guidance updates offer valuable insights that can aid in the successful development and approval of novel therapies. Engaging with these documents and integrating their recommendations into development strategies will be essential for advancing the field and improving patient outcomes.
Rethinking Chromosomal Integrity in Cell and Gene Therapy: How KROMASURE™ KBand Is Setting a New Standard KBand G-Banding Cell and gene therapy (C>) represents a frontier in modern medicine, offering unprecedented hope for treating diseases once thought incurable. However, as the science of cellular engineering advances, so too does the responsibility to ensure these engineered cells are safe, stable, and free from unintended consequences. One critical area often overlooked in traditional analytical pipelines is chromosomal integrity—specifically, the detection of low-prevalence chromosomal abnormalities that may compromise the safety of these therapies.
How KROMATID Supports IND Submissions to the FDA with High-Resolution Structural Genomic Analysis Bringing a new drug to market is a complex, multi-year endeavor filled with regulatory hurdles, and one of the earliest and most critical is the Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). A successful IND submission opens the door to clinical trials, making it a pivotal milestone for any pharmaceutical or biotech company. For developers of gene editing therapies, demonstrating genomic integrity and structural safety is essential — and that's where KROMATID comes in.
Mutagenesis: Understanding Risk Delve into the complexities and risks of mutagenesis, a critical factor in the safety and efficacy of cell and gene therapies.
Sorry, but there are no results that match your current filters and search.
Please try a different filter combination.

Stay Updated with the Latest in Next Gen Cytogenetics.

Subscribe to our blog and get:

  • Industry Insights - The latest trends shaping the biotech world.
  • Expert Advice - Learn from proven industry leaders on regulations and compliance.
  • Exclusive Updates - Be informed on new projects, products, and services.